EPs 7630, a Herbal Drug Preparation for Treating Acute Bronchitis in Children and Adults

Matthys, H; Kamin, Wolfgang

doi:10.5772/20515

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides its beneficial effects in acute bronchitis (Matthys and Kamin 2011), EPs R 7630 has previously been shown to prolong time to exacerbation of chronic bronchitis and quality of life in patients with chronic obstructive pulmonary disease (Matthys et al 2010). Thus, the present preclinical study on in vivo activity of EPs R 7630 after oral application was supplemented by examining its effect in a bacterial bronchitis in rat as well.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The existing double-blind, randomized, controlled trials on efficacy and safety of EPs 7630 in acute, viral respiratory disorders were summarized and evaluated in several reviews and meta-analyses (Matthys et al, 2013;Matthys et al, 2016;Schapowal et al, 2019;Seifert et al, 2019;Seifert et al, 2021;Kardos et al, 2022;Matthys et al, 2023). Compared to placebo, the authors consistently observed significant advantages of EPs 7630 for the efficacy outcomes assessed, i.e., the primary outcomes as assessed by disease-specific symptom scores (Matthys et al, 2016;Schapowal et al, 2019;Kardos et al, 2022) and the secondary outcomes time to substantial improvement or complete remission (Matthys et al, 2016;Schapowal et al, 2019;Seifert et al, 2019), disease-associated quality of life (QoL; Kardos et al, 2022), concomitant use of paracetamol (Matthys et al, 2016;Seifert et al, 2019;Seifert et al, 2021), and days missed at work or school (Schapowal et al, 2019;Seifert et al, 2019;Seifert et al, 2021;Matthys et al, 2023). Moreover, a systematic review and network meta-analysis demonstrated that P. sidoides extract is effective in improving the symptoms of the common cold and of acute post-viral rhinosinusitis with moderate certainty of evidence (Hoang et al, 2023).…”

Section: Introductionmentioning

confidence: 99%

Identifying in-market application of Pelargonium root extract EPs 7630 for the treatment of COVID-19: analysis of pharmacovigilance data

Malek,

Funk

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: Phytopharmaceutical products are successfully used for acute respiratory infections and may therefore be promising candidates for adjuvant symptomatic treatment of COVID-19. In vitro and clinical studies suggest that the proprietary Pelargonium sidoides DC. root extract EPs 7630 has antiviral and immunomodulatory properties, and effects on SARS-CoV-2 propagation have been shown in vitro. Medicinal products containing the extract have been approved for the symptomatic treatment of acute viral respiratory tract infections.Methods: We present a retrospective review of case reports submitted spontaneously to the pharmacovigilance database of the manufacturer of EPs 7630 and containing information on the off-label use of the extract for the treatment and prophylaxis of COVID-19 and of post-COVID-19 syndrome. Eligible case reports were identified by automated database searches.Results: Forty-four case reports filed between December 2019 and February 2023 were eligible for analysis. More than ¾ described the use of EPs 7630 for treatment of COVID-19 while the remaining reports referred to the treatment of post-COVID-19 syndrome or to COVID-19 prophylaxis. 15/22 cases which reported on treatment duration indicated an intake of EPs 7630 for up to 7 days. Five case reports indicated the use of EPs 7630 as COVID-19 monotherapy while 14 indicated a combination treatment with other drugs. All 28 cases that reported on treatment outcome characterized the patients as improved. Thirty case reports (68%) did not indicate any complications. The most frequent suspected adverse reactions were gastrointestinal complaints and hypersensitivity reactions, both of which may occur as known adverse effects of EPs 7630. No unexpected adverse reactions were observed.Conclusion: Reported cases confirm that there was a certain off-label use of EPs 7630 for COVID-19 in the market. Even though no formal conclusions about the efficacy of EPs 7630 in COVID-19 can be drawn, a beneficial effect would be explainable by the pharmacological profile of the extract. Further assessment of the effects of EPs 7630 in COVID-19-related indications therefore appears to be both justified and promising, particularly as the available case reports did not give rise to any safety concerns also in this patient group.

show abstract

Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies

Matthys

Kamin

2013

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

EPs 7630, a Herbal Drug Preparation for Treating Acute Bronchitis in Children and Adults

Cited by 3 publications

References 27 publications

Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis

Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis

Identifying in-market application of Pelargonium root extract EPs 7630 for the treatment of COVID-19: analysis of pharmacovigilance data

Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies

Contact Info

Product

Resources

About